Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 7Active not recruiting 3Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Breast Neoplasms 79Carcinoma, Non-Small-Cell Lung 71Prostatic Neoplasms 68Neoplasms 52Multiple Myeloma 46Lung Neoplasms 42Colorectal Neoplasms 37Melanoma 32Lymphoma, Non-Hodgkin 30Pancreatic Neoplasms 29Neoplasm Metastasis 29Lymphoma 28Leukemia, Myeloid, Acute 27Squamous Cell Carcinoma of Head and Neck 26Ovarian Neoplasms 26Carcinoma, Renal Cell 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Endometrial Neoplasms 22Stomach Neoplasms 20Sarcoma 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Glioma 19Uterine Cervical Neoplasms 18Recurrence 18Rectal Neoplasms 18Lymphoma, Mantle-Cell 17Hematologic Neoplasms 17Head and Neck Neoplasms 17

Interventions

blinatumomab 2tisagenlecleucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm, Residual × 30 days × Clear all
NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT04521231 2026-05-28

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Amgen

Phase 1/2 Active not recruiting
181 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen

Phase 1/2 Active not recruiting
104 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡